ClinicalTrials.gg
CompletedNCT07691203Updated Jul 8, 2026

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

A Phase 1 interventional study of Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet and Trijardy® XR Tablets in Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Diseases, sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2026, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
98th of 130
36 · median 79
Started
2026
with 7 others
Phase 1
24 of 130
5 open now
Registered
126th of 130
by date
Lead sponsor
8 of 130
Humanis Saglık Anonim Sirketi

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 98th largest by enrollment, is one of 8 that started in 2026, is one of 24 in phase 1, and was the 126th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus Trijardy® XR (Empagliflozin/linagliptin/metformin hydrochloride extended-release tablets 25 mg/5 mg/1000 mg) in healthy subject in fed condition.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 55 years old, both inclusive.
  • Gender: Male and/or non-pregnant, non-lactating female. A. Female of had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days of the first dose of study medication. They used an acceptable form of .

For female of child-bearing potential, acceptable forms of contraception included the following:

i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study.

B. Females were not considered of child-bearing potential if one of the following was reported and documented on the medical history:

i. with spontaneous amenorrhea for at least 12 consecutive months without other medical explanation, or ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iii. Total hysterectomy and an absence of bleeding for at least 3 months.

  • 18.5 to 30.0 kg/m2, both inclusive; values were rounded off to one significant digit after decimal point (e.g. 30.04 rounded down to 30.0, while 18.45 rounded up to 18.5).
  • Able to communicate effectively with study personnel.
  • Non-alcoholic, non-smoker and non-tobacco user (i.e. had no past history of drinking alcohol, smoking and tobacco consuming for at least one year prior to study).
  • Normal or clinically non-significant recording during screening.
  • Willing to provide written to participate in the study.
  • All participants were judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which included: a) A physical examination (clinical examination) with no finding.

Exclusion criteria

Exclusion Criteria:

  • History of allergic responses to Empagliflozin, Linagliptin, Metformin or other related drugs, or any of its formulation ingredients.
  • Had significant diseases or abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, recording, gynecological history and examination (including pelvic examination and routine breast examination) (for female participants)].
  • Any disease or condition like diabetes, psychosis or others, which compromised the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, Central nervous system or any other body system.
  • History or presence of bronchial asthma.
  • Used any hormone replacement therapy within 3 months prior to the first dose of study medication.
  • Used any depot injection or implant of any drug within 3 months prior to the first dose of study medication.
  • Used CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see https://drug-interactions.medicine.iu.edu/MainTable.aspx).
  • History or evidence of drug dependence.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • A positive hepatitis screen (included subtypes B \& C).
  • A positive test result for antibody.
  • Participant who had received a known drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
  • Participant who had donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever was greater.
  • History of difficulty in swallowing or of any gastrointestinal disease, which affected drug absorption.
  • Intolerance to venipuncture.
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the participant's participation in this study.
  • Institutionalized participant.
  • Used any prescribed medications within 14 days prior to the first dose of study medication.
  • Used any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
  • Used grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
  • Ingested any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeinecontaining sodas, colas, etc.), recreational drugs within 48 hours prior to the first dose of study medication.
  • Ingested any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
  • Presence of ketone during urine analysis.
  • History or presence of cardiovascular disorders.
  • Participant with Serum Lactate higher than .
  • Participant with Estimated was less than 60 ml/min/1.73 m2 during screening.
  • History or presence of hypoglycemia.
  • Participant with Serum Creatinine higher than upper limit of normal range.
  • History of acute and chronic metabolic acidosis.
  • History or sign and symptoms of pancreatitis.
  • History of genital mycotic infections.
  • History of severe and disabling arthralgia.
  • History of bullous pemphigoid.
  • History of recurrent urinary tract infection
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet

    Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet

    Drug: Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet · Drug: Trijardy® XR Tablets

  • Active comparator
    Trijardy® XR extended-release tablets

    Trijardy® XR (Empagliflozin/linagliptin/metformin hydrochloride extended-release tablets 25 mg/5 mg/1000 mg)

    Drug: Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet · Drug: Trijardy® XR Tablets

Interventions

  • DrugEmpagliflozin/Linagliptin/Metformin HCl Extended Release Tablet

    Drug pages: Empagliflozin · Linagliptin · Metformin

    1 extended Release tablet of Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg

  • DrugTrijardy® XR Tablets

    1 extended Release tablet of Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg

06

What researchers measure

Primary outcomes

  1. For Empagliflozin & Linagliptin & Metformin; Maximum concentration obtained (Cmax)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data Cmax

    Time frame: Empagliflozin & Metformin; 48 hours, Linagliptin; 72 hours

  2. For Empagliflozin & Metformin; AUC from time 0 to last collection time (AUC0 - t)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC

    Time frame: Empagliflozin & Metformin: 48 hours

  3. For Linagliptin; Area under the plasma concentration-time curve from 0 to 72 hours (AUC72)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC

    Time frame: 72 hours

Secondary outcomes

  1. For Empagliflozin & Linagliptin & Metformin; Time to reach maximum concentration Cmax (Tmax)

    Descriptive Statistics

    Time frame: Empagliflozin & Metformin: 48 hours, Linagliptin: 72 hours

  2. For Metformin : Area under the plasma concentration versus time curve from the zero time point to the last quantifiable concentration(AUCt)

    Descriptive Statistics

    Time frame: 48 hours

  3. For Empagliflozin: Area under the plasma concentration versus time curve from zero to infinity (AUCi)

    Descriptive Statistics

    Time frame: 48 hours

07

Study locations

1 site
  • Cliantha Research Limited
    Ahmedabad, Sarkhej 382210, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jun 2026, 3 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 8, 2026
StartActual
Mar 7, 2026
Primary completionActual
Jun 16, 2026
CompletionActual
Jul 1, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07691203
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Mar 7, 2026
Primary completion
Jun 16, 2026
Completion
Jul 1, 2026
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin · Metformin

Start the discussion